BetterLife Pharma Inc Total Liabilities
BetterLife Pharma Inc total liabilities. Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has total liabilities worth €6.04 Million EUR (≈ $7.06 Million USD) as of July 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NPAU cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of BetterLife Pharma Inc (2017–2025)
Total liabilities of BetterLife Pharma Inc from 2017 to 2025. This chart illustrates how BetterLife Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
BetterLife Pharma Inc Competitors by Total Liabilities
The table below lists competitors of BetterLife Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Careteq Ltd
AU:CTQ
|
Australia | AU$3.20 Million |
|
Elite Education Group International Ltd
NASDAQ:EEIQ
|
USA | $8.39 Million |
|
Future Metals NL
AU:FME
|
Australia | AU$469.06K |
|
Gulf Keystone Petroleum Ltd
LSE:GKP
|
UK | GBX157.22 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
Malaysia | RM17.69 Million |
|
Vessel Co. Ltd
KQ:177350
|
Korea | ₩17.70 Billion |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
Germany | €36.93 Million |
|
Arrive AI Inc.
NASDAQ:ARAI
|
USA | $12.87 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down BetterLife Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of BetterLife Pharma Inc.
Liquidity & Leverage Metrics
BetterLife Pharma Inc Total Liabilities Ratios Explained
BetterLife Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 26.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BetterLife Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BetterLife Pharma Inc (2017–2025)
The table below shows the annual total liabilities of BetterLife Pharma Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | €7.59 Million ≈ $8.87 Million |
-5.40% |
| 2024-01-31 | €8.02 Million ≈ $9.38 Million |
+5.42% |
| 2023-01-31 | €7.61 Million ≈ $8.89 Million |
+50.89% |
| 2022-01-31 | €5.04 Million ≈ $5.89 Million |
-15.24% |
| 2021-01-31 | €5.95 Million ≈ $6.95 Million |
+6.34% |
| 2020-01-31 | €5.59 Million ≈ $6.54 Million |
+9.99% |
| 2019-01-31 | €5.09 Million ≈ $5.95 Million |
+860.55% |
| 2018-01-31 | €529.51K ≈ $619.06K |
-74.86% |
| 2017-01-31 | €2.11 Million ≈ $2.46 Million |
-- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more